SKYWATER TECHNOLOGY INC - CLOSURE OF DEAL ANTICIPATED IN Q2 OR Q3 2026 SUBJECT TO REGULATORY APPROVALS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Should l Buy SKYT?
Source: moomoo
Deal Closure Timeline: The Skywater Technology Inc. deal is expected to close in either Q2 or Q3 of 2026.
Regulatory Approval: The completion of the deal is pending regulatory approvals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SKYT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SKYT
Wall Street analysts forecast SKYT stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.060
Low
17.00
Averages
21.50
High
25.00
Current: 33.060
Low
17.00
Averages
21.50
High
25.00
About SKYT
SkyWater Technology, Inc. is an independent, pure-play technology foundry that offers advanced semiconductor development and manufacturing services. The Company’s Technology-as-a-Service (TaaS) model leverages a foundation of proprietary technology, engineering know-how capabilities, and microelectronics manufacturing capacity to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Advanced Technology Services (ATS) for diverse microelectronics (integrated circuits (ICs)) and related micro- and nanotechnology applications. In addition to differentiated technology development services, it supports customers with volume production of ICs for high-growth markets through its Wafer Services. Its Wafer Services include the manufacture of silicon-based analog and mixed-signal ICs for its end markets. Through its ATS model, it specializes in co-creating advanced solutions with its customers that directly serve its end markets.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Merger Agreement Approved: SkyWater Technology's stockholders approved the merger agreement with IonQ at a special meeting, which will lead to IonQ acquiring SkyWater, marking a significant strategic shift for the company expected to close in Q2 or Q3 of 2026.
- Regulatory Approvals Pending: The transaction remains subject to necessary regulatory approvals and other customary closing conditions, and failure to complete these in a timely manner could disrupt the company's operational plans and divert management's focus, impacting future growth.
- Market Position Strengthened: As the largest U.S.-based pure-play semiconductor foundry, the merger will further solidify SkyWater's market position in quantum computing and next-generation systems, enhancing its capabilities in critical infrastructure and supply chain resilience.
- Forward-Looking Statement Risks: The company highlighted various risks and uncertainties associated with its forward-looking statements, including the potential inability to complete the transaction as anticipated, which could lead to a significant decline in stock price and affect investor confidence.
See More

Deal Closure Timeline: The Skywater Technology Inc. deal is expected to close in either Q2 or Q3 of 2026.
Regulatory Approval: The completion of the deal is pending regulatory approvals.
See More
Merger Agreement: Skywater Technology's shareholders have approved a merger agreement with IonQ, a quantum computing company.
Strategic Move: This merger is expected to enhance Skywater's capabilities in advanced technology and expand its market reach in the semiconductor industry.
See More
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
- New Investment Position: Palisades Investment Partners established a new position in SkyWater Technology during Q1 2026 by acquiring 260,896 shares valued at approximately $7.67 million, indicating strong confidence in the semiconductor sector.
- Outstanding Market Performance: As of April 29, 2026, SkyWater's shares were priced at $30.51, reflecting a remarkable 332.2% increase over the past year, significantly outperforming the S&P 500 by 303.8 percentage points, showcasing its robust market position.
- Strong Financial Health: SkyWater reported trailing twelve months revenue of $442.14 million and net income of $118.92 million, demonstrating solid growth and profitability in the semiconductor manufacturing industry.
- Strategic Acquisition Potential: This investment is likely linked to SkyWater's upcoming acquisition by quantum computing firm IonQ, with Palisades' stake poised for lucrative exit opportunities, while IonQ's growth potential offers substantial upside for investors.
See More

- Legal Investigation Launched: Halper Sadeh LLC is investigating Kezar Life Sciences, Inc. (NASDAQ: KZR) regarding its sale to Aurinia Pharmaceuticals Inc. for $6.955 per share and a non-transferable contingent value right, potentially infringing on shareholder rights.
- Merger Scrutiny: The firm is also examining QXO, Inc. (NYSE: QXO) and TopBuild Corp.'s merger, which may contain terms that limit superior competing offers, thereby affecting shareholder interests.
- Shareholder Rights Protection: The transaction involving SkyWater Technology, Inc. (NASDAQ: SKYT) and IonQ includes $15.00 in cash and $20.00 in IonQ common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its crucial role in protecting investor rights.
See More








